We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Merck (MRK - Free Report) was up +2.88% at $83.71. The stock outpaced the S&P 500's daily gain of 0.61%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%.
Shares of the pharmaceutical company witnessed a gain of 0.02% over the previous month, beating the performance of the Medical sector with its loss of 0.67%, and underperforming the S&P 500's gain of 3.85%.
Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2025. In that report, analysts expect Merck to post earnings of $2.04 per share. This would mark a year-over-year decline of 10.53%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.68 billion, down 2.65% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.91 per share and revenue of $64.79 billion, indicating changes of +16.47% and +0.96%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.19% downward. Right now, Merck possesses a Zacks Rank of #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 9.13. This valuation marks a discount compared to its industry average Forward P/E of 13.73.
We can also see that MRK currently has a PEG ratio of 0.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.24.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Rises Higher Than Market: Key Facts
In the latest close session, Merck (MRK - Free Report) was up +2.88% at $83.71. The stock outpaced the S&P 500's daily gain of 0.61%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%.
Shares of the pharmaceutical company witnessed a gain of 0.02% over the previous month, beating the performance of the Medical sector with its loss of 0.67%, and underperforming the S&P 500's gain of 3.85%.
Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2025. In that report, analysts expect Merck to post earnings of $2.04 per share. This would mark a year-over-year decline of 10.53%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.68 billion, down 2.65% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.91 per share and revenue of $64.79 billion, indicating changes of +16.47% and +0.96%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.19% downward. Right now, Merck possesses a Zacks Rank of #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 9.13. This valuation marks a discount compared to its industry average Forward P/E of 13.73.
We can also see that MRK currently has a PEG ratio of 0.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.24.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.